The resistance of CML patients to tyrosine kinase inhibitorshas guided the search for new compounds that may induce apoptosis inBcr-Abl+ leukemic cells and improve the diseasetreatment. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.